Literature DB >> 3469915

Clinical utility of multiple-dose administration of prostaglandin E2 gel.

T Mainprize, C Nimrod, G Dodd, D Persaud.   

Abstract

An open-label study was undertaken to assess the clinical impact of multiple doses of intracervical prostaglandin E2 (0.5 mg) gel administered at 6-hour intervals. Fifty women with low Bishop scores requiring induction of labor were recruited. The prestudy mean Bishop score was 2.3 +/- 1.1 and changed significantly with one (p less than 0.001), two (p less than 0.001), and three (p less than 0.002) doses. The mean gestational age of patients receiving three doses was significantly less than that of patients receiving one dose, (38.5 versus 40.1 weeks, p less than 0.005). Prostaglandin E2 gel induced labor in 56% of patients, but 14% required subsequent oxytocin (Syntocinon) augmentation. Cesarean section was performed in 6% of patients. No deleterious fetal, neonatal, or maternal effects occurred.

Entities:  

Keywords:  Americas; Biology; Canada; Delivery; Demographic Factors; Developed Countries; Developing Countries; Diseases; Endocrine System; Hormones; North America; Northern America; Obstetrical Surgery; Oxytocin; Physiology; Pituitary Hormones; Population; Population Dynamics; Pregnancy; Pregnancy Complications; Pregnancy Outcomes; Prostaglandins--side effects; Reproduction; Research Report; Surgery; Time Factors; Treatment

Mesh:

Substances:

Year:  1987        PMID: 3469915     DOI: 10.1016/0002-9378(87)90280-8

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  2 in total

Review 1.  Hormonal and local regulation of uterine activity during parturition: Part II--The prostaglandin and adrenergic systems.

Authors:  M Maggi; E Baldi; T Susini
Journal:  J Endocrinol Invest       Date:  1994-10       Impact factor: 4.256

2.  Prostaglandin E2 gel for cervical ripening and labour induction: a multicentre placebo-controlled trial.

Authors:  P Bernstein
Journal:  CMAJ       Date:  1991-11-15       Impact factor: 8.262

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.